Varuna Nangia

Aug 1, 2023 | science.org | Timothy Hoffman |Alexandre Martin |Annalisa M. VanHook |Varuna Nangia

Editor’s summaryFor patients with cancer driven by MAPK signaling, subsets of tumor cells often persist despite treatment with effective, targeted inhibitors. Some tumors have or develop mutations or bypass signaling to mediate drug resistance, but others lack such drivers. Hoffman et al. identified a common mechanism of tumor tolerance to MAPK pathway inhibitors.

Aug 1, 2023 | sciencemag.org | Timothy Hoffman |Alexandre Martin |Annalisa M. VanHook |Varuna Nangia

Editor’s summaryFor patients with cancer driven by MAPK signaling, subsets of tumor cells often persist despite treatment with effective, targeted inhibitors. Some tumors have or develop mutations or bypass signaling to mediate drug resistance, but others lack such drivers. Hoffman et al. identified a common mechanism of tumor tolerance to MAPK pathway inhibitors.

Jul 5, 2023 | nature.com | Hideko Isozaki |Ramin Sakhtemani |Sunwoo Oh |Susanna Monroe |Varuna Nangia |Amanda Riley | +10 more

Author notesThese authors contributed equally: Michael S. Lawrence, Aaron N. HataAuthors and AffiliationsMassachusetts General Hospital Cancer Center, Boston, MA, USAHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Faria M. Siddiqui, Nicole Phan, Daria Timonina, Samantha Bilton, Maria Gomez-Caraballo, Hannah L.